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1. Introduction  
Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal neoplasms 
of the digestive tract with an estimated annual incidence of 10–20 cases per one million 
inhabitants (H. Joensuu et al;2002, B. Nilsson, et al; 2005). GISTs probably arise from 
precursor cells of the interstitial cells of Cajal. Their defining characteristic is a gain-of-
function mutation in genes coding for the KIT tyrosine kinase receptor, which is 
considered the driving force of cell proliferation in this tumour(Y. Shinomura et al;2005) 
Gastrointestinal stromal tumors usually appear in patients above 50 years of age, whereas 
the maximum incidence is observed in the 5th and the 6th decade of life. The mean age at 
the diagnosis is 55–63 years(Tran T et al; 2005). It is very rare in children and affects males 
and females equally. GIST is mainly a disease of the GI tract, mesentery, and omentum. 
Most commonly, it originates in the stomach (60%), followed by the small intestine (30%), 
the colon and rectum (5%), and the oesophagus (5%) (Van Der Zwan SM, et al;2005). 
Fletcher et al. proposed a classification of aggressive behaviour for GISTs based on their 
maximum diameter and mitotic rate(C. D. M. Fletcher et al;2002). factors which were both 
shown to predict recurrence and survival(S. Singer et al;2002, R. P. DeMatteo et al;2000). 
GIST can present in many ways. Thirty percent are diagnosed incidentally on a 
pathological or autopsy resection specimen(B. Nilsson, et al; 2005). Small tumors may be 
asymptomatic and GISTs can grow to a large size before producing any symptoms. Most 
symptomatic patients present with tumours larger than 5 cm in maximal dimension. 
Symptoms at presentation may include abdominal pain, abdominal mass, nausea, 
vomiting, anorexia, and weight loss. The vast majority of metastatic GISTs are located 
intraabdominal, either in the liver, in the omentum, or in the peritoneal cavity(C. D. M. 
Fletcher et al;2002). Metastatic spread to lymph nodes and to other regions via lymphatics 
is very rare. Most of the patients with GIST are symptomatic and bleding due to mucosal 
ulceration is the most common symptom(Gold JS et al ; 2006). Mitotic count and tumor 
size have been shown to be very important. A large study examined 1765 tumors for 
prognostic markers(Miettinen et al; 2005 ). Tumours less than 10 cm with less than 5 
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mitoses per 50 high powered fields (HPFs) had only a 2%–3% risk of metastases. 
Conversely, the metastatic rate for tumors greater than 10 cm, with greater than 5 mitoses 
per 50 HPFs, was as high as 86%. Non-gastric primary tumor location and male gender 
may also be independent adverseprognostic factors(Rutkowski et al; 2007). Fletcher et al. 
proposed a classification of aggressive behaviour for GISTs based on their maximum 
diameter and mitotic rate(C. D. M. Fletcher et al;2002), factors which were both shown to 
predict recurrence and survival(S. Singer et al;2002, R. P. DeMatteo et al;2000). Surgery 
remains the standard initial management for all localized GIST. The tumor should be 
removed en bloc, with a clear margin. The pseudocapsule should be removed and not 
penetrated. Therefore, a wedge resection (stomach) or segmental resection (intestine) is 
required. If neighboring structures are involved, en-bloc resection should still be 
contemplated. It is mandatory that the resection achieves negative margins verified by 
intraoperative frozen section examination, since the presence of residual disease 
negatively influences survival(S. Singer et al;2002). The 5‑year survival rate after surgery 
amounts to 28–65%( Debol SM et al;2001 ,Blay JY et al;2005). It is not necessary to resect 
the regional lymph nodes during the operation, because gastrointestinal stromal tumors 
do not metastasize to the regional lymphatic system. 
2. Surgery 
Primary GIST may occur anywhere along the GI tract from the esophagus to the 
anus(Judson I et al; 2002). The most frequent site is the stomach (55%), followed by the 
duodenum and small intestine (30%), esophagus (5%), rectum (5%), colon(2%), and rare 
other locations.  
2.1 Treatment of the non-metastatic disease approach to the primary lesion (stomach) 
The radical surgical treatment is the most effective treatment option for GIST. The 5‑year 
survival rate after surgery amounts to 28–65%( R. P. DeMatteo et al;2000). It is not 
necessary to resect the regional lymph nodes during the operation, because 
gastrointestinal stromal tumors do not metastasize to the regional lymphatic system. 
Lymphatic metastasis rarely occurs (0–3.4%) in patients with GIST(Tashiro T et al; 2005). It 
is mandatory that the resection achieves negative margins verified by intraoperative 
frozen section examination, since the presence of residual disease negatively influences 
survival(S. Singer et al;2002). More recently, there has been a move to laparoscopic 
surgery, particularly for gastric GIST. One series of 50 consecutive patients showed this 
approach was associated with low morbidity and short hospitalization. All resections had 
clear margins and the long term disease free survival was 92%(Novitsky YW et al;2006). 
Current recommendation is that laparoscopy should be restricted to the treatment of 
small lesions (up to 5 cm) due to the possibility of tumor rupture as a result of the 
manipulation of larger lesions(Guitierrez JC et al;2007). Current NCCN guidelines do not 
contain a clear statement on whether surgery for GIST should be performed 
laparoscopically or through open surgery but recommend that surgery should produce 
minimal surgical morbidity(National Comprehensive Cancer Network (NCCN);2008). 
Recently, a new technique of endoscopic full-thickness resection using a flexible stapler 
was described. This approach seems particularly useful in tumours of the posterior distal 
part of the stomach(G. Kaehler et al;2006). 
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2.2 Treatment of the non-metastatic disease approach to the primary lesion (small 
intestine, duodenum and esophageal GISTs) 
GISTs of the small intestine with histopathologic features including mitotic counts >5/50 
HPF, high cellularity, absence of a predominant organoid growth pattern, absence of 
skeinoid fibers, presence of severe nuclear pleomorphism, presence of mucosal infilatration, 
and tumor cell necrosis have been significantly associated with an adverse outcome in the 
literature (Tworedk JA et al; 1997, Chang MS et al;1998). The treatment of choice is the 
complete resection of the tumour.(Figure 2) With regard to local invasion and tumor 
perforation, a tumor that has invaded a contiguous organ is considered to be advanced and 
associated with poor outcome(Shiu MH et al;1982, Ng EH et al;1992). Local invasion and 
tumor perforation were associated with poor DFS; although all gross disease was removed, 
these conditions were similar to those that occur with incomplete resections. Unlike therapy 
of mucosa and submocasa derived duodenum tumor, pancreas or duodenum resection is 
not required in therapy of duodenal stromal tumor which is tumorectomy. Unique 
treatment option of duodenal GIST is not Pancreatico-duodenectomy. Pancreas preserving 
segmental duodenum resection may be useful, comfortable and safe especially for the third  
 
 
Fig. 1. Intraoperative picture showing tumour and Meckel's diverticulum.  
(Archived by SELİM SÖZEN) 
 
 
Fig. 2. The well-circumscribed lesion of the ileum before its removal.  
(Archived by SELİM SÖZEN) 
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part GIST of duodenum. Esophageal tumors are usually small and asymptomatic, larger 
lesions present with dysphagia, and sometimes they may be found accidentally, as an 
abnormal mediastinal shadow on chest X-ray. Relevant literature reports only a few cases of 
these kinds of tumors, some treated with esophageal resection and others treated with 
enucleation (Spinelli GP et al;2008).  
 
 
Fig. 3. Histopathology slide after Immunostaining for C-Kit; Tumour cells show positivity 
after C-Kit staining, which suggests GIST. (Archived by SELİM SÖZEN) 
3. Small intestine 
The clinical presentation is variable and depends on tumor size and anatomic site. Their 
submucosal location can produce local obstructive symptoms, particularly when arising in 
the oesophagus or the small intestine. Vague upper abdominal pain, fullness, GI bleeding, 
palpable mass are other modes of presentation whereas sometimes they are found 
incidentally during barium studies, endoscopy or abdominal scans performed for other 
reasons(Roberto Logrono et al;2004). According to some authors, visceral obstruction is a 
rare occurrence even in the presence of extensive peritoneal metastatic disease( Burkill GJC 
et al;2003). Although the diagnostic procedure includes several examinations, such as 
barium examination of the gastrointestinal track, computer tomography and 
angiography(Fang SH et al;2004) , none of them can establish the correct diagnosis with 
100% certainty. The preoperative percutaneous fine needle aspiration of the tumor for 
diagnostic purpose is not indicated because of the danger for potential intraperitoneal 
migration or tumor rupture (Fang SH et al;2004). Recently, several studies pointed out the 
significance of endoscopic ultrasound-guided fine-needle aspiration for the diagnosis of 
GIST with a reported accuracy of 89% (Eloubeidi MA, et al;2004). On the other hand, 
positron-emission tomography (PET) with 18F-fluoro-2-deoxy-D-glucose is a very useful 
tool for the postoperative follow-up of patients receiving imatinib(Gelibter A et al;2004). The 
treatment of choice for GISTs is the surgical excision of the tumor. All tumors must be 
completely resected (R0 resection), where possible, including the tissues that are infiltrated, 
while systemic lymph node dissection is not recommended by many authors(Chen TW et al; 
2005, Aparicio T et al;2004). Complete surgical resection is connected with 48-65% five-year 
survival. Partial resection must only be performed in case of large tumors, for palliative 
purposes or for the control of symptoms or complications such as compression of other 
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organs, hemorrhage, or pain(Connolly EM et al;2003). The clinical presentations of GISTs of 
small bowel are variable and depend on the tumor size and anatomic site. In the review of 
Miettinen and Lasota(Miettinen M et al;2006) the most common presentation of GIST is 
reported as GI bleeding. The tumors smaller than 2 cm in size are generally asymptomatic 
and larger tumors may present with upper abdominal pain, palpable intra abdominal mass, 
vomiting, weight loss, and perforation or rupture. Computed tomography or magnetic 
resonance investigation is useful in tumors larger than 2 centimeters(Lupescu IG et al;2007, 
Spivach A et al;1999, Abbas M et al;2008). Endoscopic examinations fail in the diagnosis of 
GISTs originated from the small intestine. The long term survival is 50% at best. These 
tumors are believed to be potentially malignant lesions with an average rate of 20–25% of 
gastric and 40–50% of small intestinal localization. Metastases commonly develop in the 
abdominal cavity and liver; rarely, in bones, soft tissues, and skin (Abbas M et 
al;2008,Bucher P et al;2006, Miettinen M et al;2006). Prognostic factors for GISTs are the age, 
anatomic location, mitotic rate, and tumor size(Bucher P et al;2006, Efremidou EI et al;2006). 
Chemotherapy and radiotherapy do not increase the survival time. Radiotherapy is 
indicated in intraperitoneal hemorrhage and maintaining analgesia in unresectable tumors. 
Imatinib, a selective inhibitor of tyrosinekinases, is a hope promising drug, which is the first 
effective treatment for non-resectable or metastatic GISTs. Furthermore, imatinib is 
indicated in intraperitoneal perforated or ruptured GIST due to the possibility of peritoneal 
soiling (Efremidou EI et al;2006, Karagülle E et al;2008).  
4. Duodenum 
Duodenal GIST usually present with vague abdominal pain(50%–70%) or they bleed into the 
lumen(20%–50%)(Sturgeon C et al;2003, DeMatteo RP et al;2000). Second part of the 
duodenum seems to be the common site of duodenal GIST and most of them will require 
pancreatoduodenectomy for complete resection(Winfield et al;2006). Completely resected 
GIST has a five year survival of 30%–80%(Casper ES; 2000). Incompletely resected tumors 
have a high recurrence rate(upto 90%). Historically Unresectable/metastatic GIST has a 
median survival of 12 months(Roberts PJ et al;2002). Imatinib mesylate, a specific tyrosikine 
kinase inhibitor has produced a paradigm shift in the treatment of GIST, due to the targeted 
molecular therapy. Imatinib produce sustained clinical response in more than 50% of the 
patients with advanced GIST and one year survival in these patients was 88%(Demetri GD 
et al;2002). Surgery with negative surgical margins and no tumor rupture is a necessary and 
adequate means of treating such tumors. Extensive lymph node dissection is unnecessary, 
because GISTs rarely metastasize to the regional lymph nodes(Pidhorechly I et al;2000, 
Emory TS et al;1999, Dematteo RP et al;2000, Pieri JPEN et al;2001). When technically 
feasible, this makes duodenal resection preferable to pancreatoduodenectomy(Uehara K et 
al,2001). However, the optimal surgical treatment for duodenal GISTs has never been fully 
assessed. Recent anatomical knowledge of the head of the pancreas(Sakamoto Y et al;2000) 
has facilitated various methods of pancreatic resection for low-grade malignancies (52,53,54 
Nakagohri T et al;2000, Thayer SP et al;2002, Sakamoto Y et al; 2002), and duodenal resection 
preserving the pancreatic head can now be performed safely.  
5. Colon and rectum 
GISTs are an extremely rare subset of colonic tumors that are difficult to distinguish grossly 
from the commonly encountered adenocarcinoma. GISTs are found commonly in the 
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stomach (60 – 70%) and small intestine (20 – 30%), and rarely in the colon and rectum (5 – 
10%) and esophagus (less than 5%).(Graadt van Roggen JF et al;2001). When in a colonic 
location, about two thirds of these GISTs occur in the left or transverse colon(57 Miettien M 
et al;2000) . These tumours predominantly occur in middle aged or older persons, the 
median age at presentation being sixty years, and are uncommon below forty years of 
age(Graadt van Roggen JF et al;2001, Mukhopadyay S et al;2002). Males and females are 
affected equally, but a peculiar subset occurs in female patients below the age of 21 years, 
either singly or in association with pulmonary chondromas and extra-adrenal 
paraganglionomas (Carney’s syndrome)(Graadt van Roggen JF et al;2001).  
Grossly, GISTs may vary greatly in size. Smaller tumours (2 cm or less) are usually 
asymptomatic and are usually detected incidentally during investigations or at surgery for 
unrelated pathology. These often exhibit a benign nature, but at times, may present with 
metastasis to the liver and lungs(DeMatteo RP et al; 2000). Larger tumours usually behave 
like malignant tumors, and may present with abdominal pain and gastrointestinal bleeding 
due to ulceration of the overlying mucosa, abdominal mass, or with nonspecific symptoms 
such as weight loss, vomiting, fever and anemia. Depending on the site, the tumor may also 
present with obstruction, dysphagia, altered bowel habits, or rarely, obstructive 
jaundice(Burkill GJC et al;2003, Ludwig DJ et al;1997). Complete gross excision of the tumor 
is the treatment of choice; routine lymph node excision is not recommended since they are 
rarely involved. However, it must be stressed here that in the absence of a clear cut 
diagnosis of colonic GIST, surgery must proceed as if for adenocarcinoma and radical 
clearance should be done. Care must be taken to avoid tumour rupture during surgery, 
since this has been implicated as one of the causes of recurrence(Mukhopadyay S et al;2002, 
DeMatteo RP et al; 2000). Colorectal GISTs are relatively rare, frequency being reported at 
approximately 5%(Miettinen M et al;2000).Moreover, the pathobiological features of 
malignant GISTs of the colon remain unclear. Most rectal tumours are of epithelial origin. 
Only a small number of rectal tumours originate from the smooth muscle cells in the rectal 
wall. Such stromal tumours are either benign (leiomyoma) or show malignant characteristics 
(formerly known as leiomyosarcoma), and may have a submucosal, subserosal or 
intraluminal location(Dufresne AC et al; 1999, Buckley JA et al;1998). Malignant stromal 
tumour of the rectum represents 0.5% of all rectal tumours and 7% of gastrointestinal 
stromal tumours (GIST)(Wolf O et al;1994, Randleman CD Jr et al;1989). Macroscopically the 
tumour originates from the muscularis propria of the rectum, and the mucosa generally 
remains intact. Microscopic findings consist of a proliferation of spindle cells arranged in 
fascicles(Dufresne AC et al;1999). On endorectal ultrasound, a GIST is seen as a hypoechoic, 
heterogeneous polycyclical mass, which at high resolution ultrasound imaging is shown to 
originate from the muscularis propria(Dufresne AC et al; 1999, Marcy PY et al;1993). 
Endorectal ultrasound is very helpful in defining the extent of disease(Hsieh JS et al;1999). 
CT appearances of GIST located in the rectum do not differ from those in other parts of the 
digestive tract. On nonenhanced CT, a GIST presents as a welldelineated, lobulated, 
homogeneous soft tissue mass with low attenuation and sometimes with 
calcification(Buckley JA et al;1998, Pannu HK et al; 1999). Although GIST confined to the 
rectal wall can be treated by local excision(Cailliez-Tomasi JP et al;1999), the prognosis of 
GIST of the rectum is poor and the 5-year survival rate ranges from 22% to 66% for high 
grade malignant and low grade malignant types, respectively(Witzigmann H et al;1995). 
Tumours with mitotic counts higher than 5 per 10 high power fields, and a size larger than 
10 cm have an especially significant risk of recurrence(Miettinen M et al,1998).  
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GIST’s of the rectum are most often clinically silent. Symptoms are not specific but highly 
size-related : the tumors ranged from small asymptomatic intramural nodules to larger 
masses that bulge into the pelvis, causing compressive symptoms (pain, constipation, 
occlusion), or rectal bleeding (sudden or occult) together with anemia and urinary 
symptoms(LI C. F et al;2005). Endoscopy shows a sub-mucosal mass bulging under a 
normal or ulcerated mucosae. Per-endoscopic guided biopsies can be performed but 
remained negative in more than 50% of cases(BLAY J. Y et al;2005). Ultra-sonic endoscopy 
may revealed a hypoechogenic circular lesion with clear edges. Percutaneous needle 
biopsies have been suggested to be helpful in the diagnosis but may expose to a non-
negligible haemorrhage risk and a possible peritoneal diffusion of the tumor(BLAY J. Y et al; 
2005).  
Timing for surgery is still controversial, although some authors have published indications 
for surgery(CHANGCHIEN C. R et al;2004): lesions including malignant criteria (Group I), 
lesions less than 3 cm long with irregular edges and heterogenicity at echoendoscopy 
screening (Group II). If patients are at high operative risk, periodic biopsies and observation 
are mandatory. Lesions without malignant criteria (Group III) require echoendoscopy 
observation every 6 months. lymph node metastasis is considered an infrequent event in the 
natural evolution of these tumor. Although a limited lymphadenectomy is considered to be 
the procedure of choice. In this instance, a total mesorectum excision (TME), as strongly 
recommended for adenocarcinoma, is not mandatory for the resection of rectal GIST. More, 
extended lymph node dissection doesn’t contribute to the improvement of 
survival(APARICIO T et al;2004).  
6. Esophageal GISTs 
The presenting signs and symptoms of esophageal GIST depend on the size and location of 
the tumor. Typically, they cause dysphagia, suggesting the possibility of 
carcinoma(Miettinen M et al;2000). Less commonly they are detected as large mediastinal 
masses involving the esophagus. Other manifestations include cough, gastrointestinal 
bleeding, and weight loss. Occasionally, it may be an incidental finding. There is little 
information in the literature describing the radiologic appearance of esophageal GISTs. In 
Miettinen’s series, esophageal GISTs ranged from 2.6 to 25 cm in size and were most 
commonly located in the distal third of the esophagus . This was a distal esophageal mass 
that distorted and widened the esophageal lumen on barium esophagram(Miettinen M et 
al;2000). Although complete surgical resection is the standard treatment for localized 
resectable GISTs, the optimum extent of resection has not been determined. Surgery for 
esophageal tumors is either enucleation or esophagectomy,with the latter having a higher 
morbidity rate. Enucleation with clear dissection is sufficient for small-sized,well-capsulated 
tumors confined to the esophageal muscle layer, without mucosal lesions. Preoperative 
biopsy and esophagectomy, however, should be considered for larger tumors or tumors 
accompanied by mucosal lesions. Clear resection margins are also important. In performing 
enucleation, we shelled out the tumor carefully. with Endo Peanut (U.S. Surgical, Norwalk, 
CT). And rather than assessing margin status, we determined whether the tumor capsule 
was maintained in intact condition, as well as confirming mucosal integrity, by 
intraoperative endoscopic examination. During esophagectomy the external lateral margin 
as well as the proximal and distal resection margins was confirmed by pathologic 
examination. Although small intestinal and gastric GISTs may be resected with segmental or 
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wedge resections, esophageal GIST resections are essentially limited to either simple 
enucleation or esophagectomy. Successful surgical treatment of GISTs depends on complete 
local resection. The approach to esophagectomy for GISTs should minimize blunt or blind 
dissection as this will not reliably include maintaining the thin potential barrier of pleura 
that may overlie extramucosal tumor. Additionally, poor tumor integrity and lack of 
esophageal serosa increase the risk of tumor rupture with blunt dissection. Transhiatal 
esophagectomy would likely violate tumors of the distal and midesophagus that extend 
beyond the muscularis and cannot be recommended. A transthoracic en bloc resection of the 
pleura overlying the esophagus and any involved surrounding tissues, including 
diaphragm, is advisable to avoid microscopically or macroscopically incomplete resection. A 
left thoracoabdominal approach is advocated for larger tumors at the gastroesophageal 
junction as this will allow excellent visualization of the parahiatal tissue. Management 
guidelines for GISTs have been defined by consensus of the National Comprehensive 
Cancer Network (NCCN) and the European Society of Medical Oncology(Demetri GD et 
al;2006, Blay JY et al;2005). The NCCN guidelines state that enucleation of small (_2 cm) 
esophageal GIST may be acceptable and that small intraabdominal tumors might be resected 
laparoscopically.  
6.1 Treatment of the non-metastatic disease approach to the primary lesion (extra 
gastrointestinal tumors and Meckel's diverticulum) 
GIST also occur in the extra-intestinal abdominopelvic sites such as the omentum, 
mesentery, or retroperitoneum. A small number may originate not from the omentum, but 
from outside the gastrointestinal tract; these are designated extra-GISTs (EGISTs)(Reith JD et 
al;2000). The reported cases of extra-gastrointestinal stromal tumors (EGIST) have included 
omental, mesenteric, and retroperitoneal tumors. The cellular origin of GIST from the 
interstitial cell of Cajal (ICC) raises the question of whether these EGIST are truly an entity 
analogous to GISTs. It is not well known if extra-gastrointestinal stromal tumors (EGIST) 
originate from pacemaker cells outside of the GI tract or if mesenchymal cells have the 
ability to recapitulate the phenotype. Sakurai et al.(Sakurai S et al;2001), published their 
results on the cytological, immunohistochemical, and genetic analysis of 5 omental 
mesenchymal tumors in 2001. They found all five tumors to be positive for CD117 and CD34 
staining, while all were negative for smooth-muscle cell markers. More importantly, the 
authors reported finding KIT immunoreactive CD117 and CD34 cells within specimens of 
omentum(Sakurai S et al;2001). These findings and those of Yamamoto et al.( Yamamoto H 
et al;2004) underscore the fact that histologically, EGISTs have a similar appearance to 
GISTs, and that EGIST is a distinctive entity, different from leiomyosarcomas(Miettinen M et 
al;1999). The most common mutation of the KIT gene occurred in exon 11 in Sakurai's and 
Yamamoto's experience(Sakurai S et al;2001, Yamamoto H et al;2004 ).  
GIST arising from Meckel's diverticulum are extremely rare(Johnston AT et al;2001). (Figüre 
1,3). The tumors are infrequent and observed only in 0.5–3.2% of the Meckel's diverticula. Of 
these, 12% tumors are GIST. Radiological appearances of GIST may include asymmetrical 
thickening of the bowel wall initially, but more commonly an exophytic soft tissue mass 
with relatively well defined margins is seen( Macari M et al;2001). Areas of necrosis are 
present in up to 70% of tumours(Nicola´s AI et al;1999) and particularly in larger tumours 
that frequently undergo central necrosis, due to rapid growth, and subsequent ischaemia 
(Macari M et al;2001). These also demonstrate heterogeneous contrast enhancement (Macari  
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M et al; 2001). Areas of calcification and haemorrhage are seen within 7% and 64% of 
tumours, respectively(Nicola´s AI et al;1999).Surgical resection is the treatment of choice for 
these tumors, which usually have a poor prognosis. Extragastrointestinal stromal tumors 
arising in the pancreas are extremely rare. A primary localization in the pancreas has rarely 
been reported on cytology. The clinical symptoms include abdominal pain, early satiety, 
flatulence, ileus, bleeding, anemia, and weight loss. It can be diagnosed incidentally by 
radiologic imaging(Miettinen M;2001). There was a distinct female predominance, age 
ranging from 38 to 72 years including all surgical pathological cases (mean age 55 years). 
The majority occurred in the body and tail of the pancreas with an average size of 12 
cm(Miettinen M;2001). Extraintestinal gastrointestinal stromal tumors (EGISTs) are 
uncommon and unique neoplasms, usually involving the mesentery, omentum, 
retroperitoneum, rarely bladder( Nagase S et al;2007) and inguinal hernial sac. EGISTs 
arising in the rectovaginal septum and presenting as a recurrent vaginal mass is unusual. 
The current definitive treatment for EGIST is surgical resection, but in majority of the 
patients, the tumors recur despite complete resection(Dematteo RP et al;2000). An accurate 
diagnosis is mandatory for EGIST as these are tumors with an aggressive course and a 
potential for recurrence inspite of complete surgical excision. In addition, the treatment 
strategy includes kit tyrosine inhibitor, Imatinib which is used for recurrent and advanced 
disease.  
6.2 Treatment of the metastatic and relapsed disease 
GISTs have a high risk of metastatic relapse. The usual site of recurrence is the liver 
(65%), the peritoneal surface (50%) and both (20%). GIST's response to conventional 
chemotherapy is very poor (<10%), while radiotherapy is only used for analgesic 
purposes or in cases of intra peritoneal hemorrhage (Gupta P et al; 2008). Surgery has 
limited efficacy in the treatment of recurrent and metastatic GIST. In the past years, there 
has been no efficient method to cure recurrent GIST. GIST is also resistant to both 
chemotherapy and radiotherapy. The development of imatinib has improved the 
management of GIST. Even though imatinib is effective for most patients with a 
metastatic GIST, the development of resistance to the drug is a problem that has been 
increasing(Heinrich MC;2006). Based on the satisfied result for advanced GIST, surgery 
combined with imatinib adjuvant therapy may give a hope for the patients with high-
risk GISTs. A prospective multicenter trial in high-risk patients after complete gross 
resection of the tumor revealed that imatinib 400 mg daily can reduce the risk of 
recurrence and metastasis(Zhan WH et al;2006). Based on the satisfied result for 
advanced GIST, surgery combined with imatinib adjuvant therapy may give a hope for 
the patients with high-risk GISTs(Zhan WH et al;2006). Although there are several 
reports of combination therapy of imatinib with surgery for the advanced GIST with 
metastases, most of the studies used imatinib eoadjuvantly, and the surgery was 
performed after the reduction of tumor burden by imatinib therapy. For tumours with a 
larger diameter and/or unfavourable location, primary wedge resection is often not 
possible and total or subtotal gastrectomy would be required for resection with tumour-
free margins. For these cases, the NCCN guidelines(National Comprehensive Cancer 
Network (NCCN);2008) and ESMO recommendations(P. G. Casali et al;2008) suggest 
neoadjuvant imatinib therapy to decrease tumour size, thus fallowing for organ-
preserving surgery.  
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7. Laparoscopic resection 
The latest ESMO Clinical Recommendations consider a laparoscopic approach “if cancer 
surgery principles are respected.” (P. G. Casali et al;2008). Current NCCN guidelines do not 
contain a clear statement on whether surgery for GIST should be performed 
laparoscopically or through open surgery but recommend that surgery should produce 
minimal surgical morbidity(National Comprehensive Cancer Network (NCCN);2008). 
Current recommendation(Guitierrez JC et al;2007) is that laparoscopy should be restricted to 
the treatment of small lesions (up to 5 cm) due to the possibility of tumor rupture as a result 
of the manipulation of larger lesions(Guitierrez JC et al;2007). Although oncologic success 
has been reported with laparoscopic resections(Catena F et al;2008), studies with a larger 
number of cases and long-term follow-up are required in order to define the actual role of 
laparoscopy in the treatment of this neoplasm. Laparoscopic surgery as the new “gold 
standard” in the treatment of localised GISTs of the stomach, it would be highly desirable to 
have results from one or several randomised controlled trials(S. Sauerland et al;1999). As in 
other laparoscopic procedures, the existence of a “learning curve”must be assumed and it 
can be expected that operation times further decrease with growing experience(S.Avital et 
al;2006, M. Lim et al;2006, R. B. Shin et al,2005).  
8. Conclusion 
Although rare among tumors involving the gastrointestinal system, gastrointestinal stromal 
tumors are the most frequent mesenchymal tumors. Recommended treatment regimens 
need to be updated as the multidisciplinary approach to both diagnosis and treatment of the 
tumor gains importance. Surgery still holds place as the most important constituent of 
multidisciplinary in current algorythms and ongoing studies. The introduction of imatinib 
in clinical practice(Joensuu H et al;2001). changed not only the survival of metastatic GIST 
patients, but also meant breaking through well established paradigms. Nevertheless, despite 
the advances and the encouraging outcomes with the use of imatinib, the surgeon still has a 
key role in the management of GIST( Linhares E et al;2006).  
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